Impact on survival without chemotherapy of local treatments of lung metastasis of colorectal cancers: Analysis on REPULCO cohort.

The impact of local management of pulmonary metastases on the disease course of patients with metastatic colorectal cancer is poorly assessed. REPULCO database was a retrospective cohort on 18 years that included all patients treated for lung metastases from colorectal cancer who received local and/or systemic treatments. Primary objective was overall survival, secondary were progression-free survival and survival without chemotherapy. Three hundred and fifteen patients were analyzed, 157 with only systemic treatments, 78 with only local treatments, and 80 with local and systemic treatments. Overall survival at 5 years was 26.9% (IC95%: [17.7–36.9]) for systemic treatments only, 61.0% (IC95%: [40.8–76.1]) for local treatments only, and 77.8% (IC95%: [60.1–88.3]) for local and systemic treatments. Progression-free survival at 2 years was 4.8% (IC95%: [2.1–9.2]) for systemic treatment only, 28.3% (IC95%: [17.7–39.9]) for local treatments only, and 21.8% (IC95%: [13.1–31.9]) for local and systemic treatments. Median survival without chemotherapy was 2.99 months (IC95%: [2.33–3.68]) for systemic treatments, 33.97 months (IC95%: [19.06-NA]) for local treatments, and 12.85 months (IC95%: [8.18–21.06]) for local and systemic treatments. Local treatments of lung metastasis led to prolonged survival and allowed long periods of time without chemotherapy in this cohort. [ABSTRACT FROM AUTHOR]